New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan

Hot Topics in Hypertension

Volumn , Issue 8, 2009, Pages 7-15

  Barrios, Vivencio ^a   Escobar, Carlos ^a   Echarri, Rocio ^a   De Alvaro, Fernando ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN MEDOXOMIL; LISINOPRIL; LOSARTAN; NITRENDIPINE; OLMESARTAN; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FLU LIKE SYNDROME; GLOMERULUS FILTRATION RATE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; METABOLIC DISORDER; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77953397766     PISSN: 1973963X     EISSN: 20360908     Source Type: Book Series    
DOI: 10.4147/hth-090800     Document Type: Review

References (84)

1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414.
2. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics: 2005 edition. London: British Heart Foundation; 2005.
3. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-1619.
4. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006;1:8-18.
5. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
6. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636.
7. Ruilope KM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001;12:218-225.
8. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
9. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356- 360.
10. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418.
11. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-2039.
12. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988;2:530-533.
13. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjær H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 2003;42:466-473.
14. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-906.
15. Hillege HL, Fidler V, Diercks GF, et al; for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782.
16. Barrios V, Escobar C, Murga N, et al. Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens 2008;26:2230-2235.
17. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35 (Suppl 1):S117-S131.
18. Barrios V, Escobar C, Echarri R. Chronic kidney disease: the forgotten cardiovascular risk factor. Int J Clin Pract 2009;63:962-965.
19. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187.
20. Volpe M. Angiotensin II: an amplifier of cardiovascular risk. Curr Hypertens Rep 2004;6:247-248.
21. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003;21:1429-1443.
22. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 2005;112:110-16.
23. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208- 1219.
24. Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother 2008;9:129-36.
25. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009;76:23-31.
26. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
27. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
28. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
29. Schmieder RE. The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 2005;20:2610-2612.
30. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996;94:1304-1309.
31. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46.
32. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005;18:1563-1569.
33. Escobar C, Barrios V, Calderón A, et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008;10:208-214.
34. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003;21:1213-1220.
35. Volpe M, Tocci G. Renal protection with telmisartan: a key target when managing hypertension and diabetes. Hot Topics in Hypertension 2007;1:7-27.
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000;342:145-153.
37. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hypertens 2002;20:405-412.
38. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005;45:526-529.
39. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007.
40. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75.
41. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyöörä lä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-940.
42. Barrios V, Escobar C, Calderón A, Echarri R, González-Pedel V, Ruilope LM; CONTROLRISK Investigators. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007;21:479-485.
43. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-462.
44. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:72-78.
45. Barrios V, Escobar C, Llisterri JL, et al. [Blood pressure and lipid control and coronary risk in the hypertensive population attended in Primary Care setting in Spain. The PRESCOT study]. Rev Clin Esp 2007;207:172-178.
46. McInnes GT. Antihypertensive drugs in combination: additive or greater than additive? J Hum Hypertens 2007;21:914-916.
47. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl):2-6.
48. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol 2009 (in press).
49. Wing LM, Reid CM, Ryan P, et al; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
50. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
51. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
52. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
53. Barrios V, Escobar C, Calderón A, et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006;7:236-242.
54. Barrios V, Calderón A, Escobar C, et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens 2007;25:1967-1973.
55. Mochizuki S, Dahlof B, Shimizu M, et al; for the Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431- 1439.
56. Schrader J, Luders S, Kulschewski A, et al; MOSES Study Group. Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.
57. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
58. Barrios V, Escobar C, Echarri R. Importance of medication adherence from the ONTARGET and TRANSCEND points of view. Fundam Clin Pharmacol 2009;23:259-260.
59. Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet 2008;372:535-536.
60. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
61. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009;7:229-239.
62. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16 (Suppl. 2):S24-S28.
63. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-432.
64. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004;26 Suppl A: A33-A37.
65. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
66. Stumpe KO, Agabiti-Rosei E, Zielinski T, et al; MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007;1:97-106.
67. Smith RD, Yokoyama H, Averill DB, Schiffrin EL, Ferrario CM. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertens 2008;2:165-172.
68. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-259.
69. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007;27:545-558.
70. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008;10:911-921.
71. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007;9:36-44.
72. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2007;9:45-48.
73. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-2092.
74. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006;20:255-262.
75. Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168-174.
76. Rump LC, Ambrosioni E, Burnier M, Horl W, Rabelink AJ. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20:299-301.
77. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19 (Suppl. 1):S49-S56.
78. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569-577.
79. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006;23:680-695.
80. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007;25:2168-2177.
81. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006;6:103-113.
82. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007;7:361-372.
83. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-408.
84. Imai E, Ito S, Haneda M, Chan JC, Makino H; ORIENT Investigators. Olmesartan reducing incidence of endstage renal disease in diabetic